Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial designCentral MessagePerspective
Objective: The safety and feasibility of preoperative pembrolizumab combined with chemoradiotherapy (PPCT) for resectable esophageal squamous cell carcinoma have been confirmed by the prior Preoperative Anti-PD-1 Antibody combined with Chemoradiotherapy for Locally Advanced Squmous Cell Carcinoma of...
Main Authors: | Yuyan Zheng, MD, Chengqiang Li, MD, PhD, Bentong Yu, MD, Shengguang Zhao, MD, Jian Li, MD, PhD, Xiaoyan Chen, MD, Hecheng Li, MD, PhD, FACS |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-03-01
|
Series: | JTCVS Open |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666273621004228 |
Similar Items
-
Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort
by: Wei‐Xiang Qi, et al.
Published: (2023-06-01) -
A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
by: Christopher A. Lemmon, MD, et al.
Published: (2022-07-01) -
The addition of pembrolizumab to neoadjuvant chemoradiotherapy did not increase the risk of developing postoperative anastomotic leakage for ESCC: an analysis from a prospective cohort
by: Wei-Xiang Qi, et al.
Published: (2024-08-01) -
Pacemaker implantation following tricuspid valve annuloplastyCentral MessagePerspective
by: Sigurdur Ragnarsson, MD, PhD, et al.
Published: (2023-12-01) -
2-CONSERVATIVE TREATMENT OF RECTAL ADENOCARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY, IS IT ACCEPTABLE?
by: Majeed H Alwan
Published: (2009-06-01)